Zobrazeno 1 - 10
of 120
pro vyhledávání: '"J Sánchez-Rubio"'
Autor:
L Martín Zaragoza, J Sánchez-Rubio Ferrandez, A Onteniente González, M Gómez Bermejo, A Alcántara Prado, L Carmona Juárez, SJ Rodriguez Álvarez, A Monereo Alonso, T Molina Garcia
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::860880212d862a8b50d81adbf22ed9dd
https://doi.org/10.1136/ejhpharm-2023-eahp.158
https://doi.org/10.1136/ejhpharm-2023-eahp.158
Autor:
Á López García, L Martín-Zaragoza, L Rubio-Ruiz, C Martínez-Nieto, M Velez-Diaz-Pallares, P Sanmartin-Fenollera, JA Peña-Pedrosa, A Onteniente-González, LM Bedoya-del-Olmo, I Iglesias-Peinado, J Sánchez-Rubio-Ferrández
Publikováno v:
Section 6: Education and research.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3295c108a04a966c24ea3e0497d09df2
https://doi.org/10.1136/ejhpharm-2023-eahp.352
https://doi.org/10.1136/ejhpharm-2023-eahp.352
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
I Patier, N Herranz-Muñoz, F Fernandez Fraga, J Sánchez-Rubio Ferrández, I García-Bermejo, M Moreno-García, T Molina-Garcia
Publikováno v:
Section 7: Post Congress additions.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6ea82a07cb773e6f70071858942f76f
https://doi.org/10.1136/ejhpharm-2022-eahp.381
https://doi.org/10.1136/ejhpharm-2022-eahp.381
Autor:
L Rubio-Ruiz, C Martín-Blas, J Sánchez-Rubio, N Ibañez-Heras, T Molina-García, L Martín-Zaragoza, FJ Alonso-Zazo, F Fernández-Fraga
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f136caad879a600877641c8fe19902a8
https://doi.org/10.1136/ejhpharm-2022-eahp.180
https://doi.org/10.1136/ejhpharm-2022-eahp.180
Autor:
N Herranz-Muñoz, J Sánchez-Rubio Ferrández, L Martín-Zaragoza, M Gómez-Bermejo, S Solís-Cuñado, T Molina-García
Publikováno v:
Section 7: Post Congress additions.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce4035c7178eb94dc5365030901fc6e0
https://doi.org/10.1136/ejhpharm-2022-eahp.394
https://doi.org/10.1136/ejhpharm-2022-eahp.394
Autor:
Á López-García, N Herranz-Muñoz, I Salvador-Llana, P Sanmartín-Fenollera, M Vélez-Díaz-Pallarés, JA Peña-Pedrosa, C Martínez-Nieto, A Onteniente-González, LM Bedoya-Del-Olmo, I Iglesias-Peinado, J Sánchez-Rubio-Ferrández
Publikováno v:
Section 7: Post Congress additions.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5bac10001fc5ee99e33e4c82381c8ac
https://doi.org/10.1136/ejhpharm-2022-eahp.407
https://doi.org/10.1136/ejhpharm-2022-eahp.407
Autor:
Á López-García, N Herranz-Muñoz, I Salvador-Llana, P Sanmartín-Fenollera, M Vélez-Díaz-Pallarés, JA Peña-Pedrosa, C Martínez-Nieto, A Onteniente-González, LM Bedoya-Del-Olmo, I Iglesias-Peinado, J Sánchez-Rubio-Ferrández
Publikováno v:
Section 7: Post Congress additions.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::493f5d1e97083386867ef2a70bc7d80d
https://doi.org/10.1136/ejhpharm-2022-eahp.408
https://doi.org/10.1136/ejhpharm-2022-eahp.408
Autor:
Manuel Cordoba-Diaz, Teresa Molina-Garcia, R Vázquez-Sánchez, Damián Cordoba-Diaz, J Sánchez-Rubio-Ferrández
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:1076-1081
Carboplatin hypersensitivity reactions are one of the major clinical challenges in treating patients with relapse/recurrent ovarian malignancies. Desensitization protocols allow the continuation of treatment in patients who have presented hypersensit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad1b993ab13f1e62980a0bdaa167dcd3
https://doi.org/10.1177/1078155218772885
https://doi.org/10.1177/1078155218772885
Autor:
Teresa Molina-Garcia, Á Aragón-Díez, JM Rodríguez-Heredia, I Cavada Carranza, J Sánchez-Rubio-Ferrandez, FJ Alonso-Zazo, ME Martínez-Núñez, R Vázquez-Sánchez
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Therapeutic decision-making for biologic-therapies (BT) dose optimisation should be based on optimal disease activity results. The goal of BT optimisation is to guarantee long-term effectiveness and safety, maximising economic savings. Pur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a7c27b24c729ccb99bfa284d921d907
https://doi.org/10.1136/ejhpharm-2019-eahpconf.290
https://doi.org/10.1136/ejhpharm-2019-eahpconf.290